Andrew Adams is Senior Vice President of Neurodegeneration Research and is Co-Director of the Lilly Institute for Genetic Medicine at Eli Lilly and Company. He is responsible for leading the discovery of new types of therapies, such as genetic medicines at Lilly, via both internal research and robust collaborations with external partners. These novel approaches will allow access to previously undruggable targets across the breath of therapeutic areas at Lilly, as well as potentially opening novel avenues of clinical investigation.

Andrew holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, Andrew was a postdoctoral fellow at Harvard Medical School studying the neurobiology of anorexia nervosa. During his time at Lilly, he has served in roles in early discovery, external innovation and as a leader of Lilly’s early trailblazer teams, championing new ways to bring Lilly science to patients with speed.